Sato Itaru, Ueda Nobuhiko, Kinoshita Eriko, Minato Hiroshi, Ohno Kenji, Nakaya Naoki, Shimasaki Takeo, Nakajima Hideo, Kosaka Takeo, Motoo Yoshiharu
Department of Medical Oncology, Kanazawa Medical University.
Gan To Kagaku Ryoho. 2010 Jul;37(7):1341-4.
A 73-year-old man diagnosed as having pancreatic body cancer with multiple liver metastases was referred to our hospital. Since the patient preferred oral agents, S-1 monotherapy (4-week administration followed by 2-week interval) was started. The initial dose of S-1 was 80 mg, and gradually increased to 150 mg/day. There were no significant adverse events. The liver metastases disappeared and the pancreatic tumor was markedly reduced in size at the completion of 4 courses. Distal pancreatectomy was carried out at 7 months since his first visit. Pathological diagnosis was non-functioning well-differentiated neuroendocrine carcinoma (pT4, pN0, pM0, Stage IVa). He is alive without relapse 6 months after operation. S-1 might be a candidate for chemotherapy for this neuroendocrine tumor.
一名73岁男性被诊断为胰体癌伴多发肝转移,随后转诊至我院。由于患者倾向于口服药物,遂开始使用S-1单药治疗(给药4周,随后间隔2周)。S-1初始剂量为80mg,并逐渐增至150mg/天。未出现明显不良事件。在完成4个疗程时,肝转移灶消失,胰腺肿瘤大小显著缩小。自首次就诊7个月后进行了胰体尾切除术。病理诊断为无功能性高分化神经内分泌癌(pT4,pN0,pM0,IVa期)。术后6个月,患者存活且未复发。S-1可能是这种神经内分泌肿瘤化疗的一个选择。